Evommune, Inc. (EVMN) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

$445.30M

MomentumView details →

1D Return

+2.25%

YTD Return

−28.62%

RSI (14)

39.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

$445.30M

RSI (14)

39.3

MomentumView details →

1D Return

+2.25%

YTD Return

−28.62%

ProfitabilityView details →

Gross Margin

96.51%

Net Margin

−946.68%

EBITDA Margin

−957.79%

ROE (TTM)

−34.10%

ROA (TTM)

−31.35%

Asset Turnover

0.03x

GrowthView details →

Revenue YoY

+233.33%

EPS YoY

+14.50%

FCF YoY

+7.97%

Revenue CAGR 3Y

+61.25%

EPS CAGR 3Y

+3.96%

EBITDA YoY

−31.11%

EarningsView details →

EPS (Actual)

−$0.89

EPS Surprise

−33.94%

Beats (12Q)

1/12

Next Q EPS Est

−$0.84

Avg Surprise (4Q)

−236.12%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

11.68x

Quick Ratio

11.68x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

10.00M

Net Income (TTM)

−94.67M

Op. CF (TTM)

−74.15M

Next earningsOct 16, 2026 →

Latest newsMore news →

Evommune's phase IIb clinical trial for EVO756 in chronic spontaneous urticaria failed to meet its primary endpoint.66d ago

Similar companies

Genfit S.A.GNFT Shanghai Bio-heart Biological Technology Co., Ltd.02185.HK Vogenx Inc.VOGX Rezolute, Inc.RZLT Arcturus Therapeutics Holdings Inc.ARCT BioAge Labs, Inc.BIOA Find similar companies →

Latest newsMore news →

Evommune's phase IIb clinical trial for EVO756 in chronic spontaneous urticaria failed to meet its primary endpoint.66d ago